Patents by Inventor Lan Jiang

Lan Jiang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE
    Publication number: 20200317689
    Abstract: Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2, L, W1, W2, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: March 20, 2020
    Publication date: October 8, 2020
    Inventors: Hang Chu, Ana Z. Gonzalez Buenrostro, Hongyan Guo, Xiaochun Han, Lan Jiang, Jiayao Li, Michael L. Mitchell, Hyung-Jung Pyun, Scott D. Schroeder, Gregg M. Schwarzwalder, Nathan D. Shapiro, Devleena M. Shivakumar, Qiaoyin Wu, Hong Yang, Jennifer R. Zhang
  • Amino acid compounds and methods of use
    Patent number: 10793564
    Abstract: The invention relates to compounds of formula (A) and formula (I): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: October 6, 2020
    Assignee: PLIANT THERAPEUTICS, INC.
    Inventors: Jacob Cha, Chengguo Dong, Timothy Hom, Lan Jiang, Katerina Leftheris, Hui Li, David J. Morgans, Jr., Manuel Munoz, Maureen Reilly, Yajun Zheng
  • 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
    Patent number: 10745394
    Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: August 18, 2020
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Daniel D. Long, John R. Jacobsen, Lan Jiang, Ioanna Stergiades, Priscilla M. Van Dyke
  • MCL-1 inhibitors
    Patent number: 10703733
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: July 7, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • Amino acid compounds and methods of use
    Patent number: 10696672
    Abstract: The invention relates to compounds of formula (I): formula (I) or a salt thereof wherein R1, R5, R7, R8, X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: June 30, 2020
    Assignee: Pliant Therapeutics, Inc.
    Inventors: David John Morgans, Jr., Randall L. Halcomb, Gustave Bergnes, Hui Li, Lan Jiang, Jacob Cha, Timothy Hom
  • 2-AZABICYCLO HEXANE JAK INHIBITOR COMPOUND
    Publication number: 20200131178
    Abstract: The invention provides a compound of formula 1 or a pharmaceutically-acceptable salt thereof, that is useful as a JAK inhibitor. The invention also provides pharmaceutical compositions comprising the compound, methods of using the compound to treat diseases amenable to a JAK inhibitor, and processes useful for preparing the compound.
    Type: Application
    Filed: October 18, 2019
    Publication date: April 30, 2020
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul R. Fatheree, Lan Jiang
  • METHOD FOR PRECISION CANCER TREATMENT BY IDENTIFYING DRUG RESISTANCE
    Publication number: 20200113476
    Abstract: A method for precision cancer treatment by identifying drug resistance is provided.
    Type: Application
    Filed: December 10, 2019
    Publication date: April 16, 2020
    Inventor: Lan Jiang
  • N-acyl amino acid compounds and methods of use
    Patent number: 10604520
    Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, A, L, and R2 and n are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?1 integrin inhibitors that are useful for treating tissue specific fibrosis.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: March 31, 2020
    Assignee: Pliant Therapeutics, Inc.
    Inventors: Lan Jiang, David John Morgans, Jr., Gustave Bergnes, Chun Chen, Hui Li, Patrick Andre, Randall L. Halcomb, Jacob Cha, Timothy Hom
  • FUSED IMIDAZO-PIPERIDINE JAK INHIBITOR COMPOUND
    Publication number: 20200046719
    Abstract: The invention provides a compound of formula 1 or a pharmaceutically-acceptable salt thereof, that is useful as a JAK inhibitor. The invention also provides crystalline forms of the compound, pharmaceutical compositions comprising the compound, methods of using the compound to treat diseases amenable to a JAK inhibitor, and processes and intermediates useful for preparing the compound.
    Type: Application
    Filed: October 18, 2019
    Publication date: February 13, 2020
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: ROBERT MURRAY MCKINNELL, VENKAT R. THALLADI, HAO ZHANG, PAUL R. FATHEREE, LAN JIANG, MARTA DABROS, JERRY NZEREM
  • JAK kinase inhibitor compounds for treatment of respiratory disease
    Patent number: 10526330
    Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: January 7, 2020
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Paul R. Fatheree, John R. Jacobsen, Gary E. L. Brandt, Melissa Fleury, Lan Jiang, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden, Anne-Marie Beausoleil
  • Fused imidazo-piperidine JAK inhibitor compound
    Patent number: 10493077
    Abstract: The invention provides a compound of formula 1 or a pharmaceutically-acceptable salt thereof, that is useful as a JAK inhibitor. The invention also provides crystalline forms of the compound, pharmaceutical compositions comprising the compound, methods of using the compound to treat diseases amenable to a JAK inhibitor, and processes and intermediates useful for preparing the compound.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: December 3, 2019
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul R. Fatheree, Lan Jiang, Venkat R. Thalladi, Marta Dabros, Jerry Nzerem
  • MCL-1 INHIBITORS
    Publication number: 20190352271
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Application
    Filed: May 13, 2019
    Publication date: November 21, 2019
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • AMINO ACID COMPOUNDS AND METHODS OF USE
    Publication number: 20190322663
    Abstract: The invention relates to compounds of formula (I): formula (I) or a salt thereof wherein R1, R5, R7, R8, X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    Type: Application
    Filed: December 20, 2017
    Publication date: October 24, 2019
    Inventors: David John MORGANS, Jr., Randall L. HALCOMB, Gustave BERGNES, Hui LI, Lan JIANG, Jacob CHA, Timothy HOM
  • 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20190308966
    Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: June 24, 2019
    Publication date: October 10, 2019
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Daniel D. Long, John R. Jacobsen, Lan Jiang, Ioanna Stergiades, Priscilla M. Van Dyke
  • AMINO ACID COMPOUNDS AND METHODS OF USE
    Publication number: 20190276449
    Abstract: The invention relates to compounds of formula (A) and formula (I): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    Type: Application
    Filed: March 7, 2019
    Publication date: September 12, 2019
    Inventors: Jacob CHA, Chengguo DONG, Timothy HOM, Lan JIANG, Katerina LEFTHERIS, Hui LI, David J. MORGANS, JR., Manuel MUNOZ, Maureen REILLY, Yajun ZHENG
  • 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
    Patent number: 10377751
    Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: August 13, 2019
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Daniel D. Long, John R. Jacobsen, Lan Jiang, Daisuke Roland Saito, Ioanna Stergiades
  • 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20190119267
    Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: August 16, 2018
    Publication date: April 25, 2019
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Daniel D. Long, John R. Jacobsen, Lan Jiang, Daisuke Roland Saito, Ioanna Stergiades
  • JAK Kinase Inhibitor Compounds for Treatment of Respiratory Disease
    Publication number: 20190106420
    Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: December 10, 2018
    Publication date: April 11, 2019
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul R. Fatheree, John R. Jacobsen, Gary E.L. Brandt, Melissa Fleury, Lan Jiang, Cameron Smith, Steven D.E. Sullivan, Lori Jean Van Orden, Anne-Marie Beausoleil
  • Air conditioning device
    Patent number: 10234152
    Abstract: An air conditioner disclosed herein includes a cooling/heating module including a thermoelastic material and an actuator applying tension to the thermoelastic material and a switching control section selectively applying or removing tension to/from the thermoelastic material.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: March 19, 2019
    Assignee: Daikin Industries, Ltd.
    Inventors: Shuji Ikegami, Yukihiro Makino, Kouichi Yasuo, Hyunyoung Kim, Makoto Kojima, Mamoru Okumoto, Chuncheng Piao, Lan Jiang
  • FUSED IMIDAZO-PIPERIDINE JAK INHIBITOR COMPOUND
    Publication number: 20180311255
    Abstract: The invention provides a compound of formula 1 or a pharmaceutically-acceptable salt thereof, that is useful as a JAK inhibitor. The invention also provides crystalline forms of the compound, pharmaceutical compositions comprising the compound, methods of using the compound to treat diseases amenable to a JAK inhibitor, and processes and intermediates useful for preparing the compound.
    Type: Application
    Filed: April 30, 2018
    Publication date: November 1, 2018
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: PAUL R. FATHEREE, LAN JIANG, ROBERT MURRAY MCKINNELL, VENKAT R. THALLADI, HAO ZHANG, MARTA DABROS, JERRY NZEREM, NOAH BENJAMIN, MELANIE A. KLEINSCHEK, GLENN D. CRATER